This case study describes the development and validation of an ELISA method to quantify total antibody (tAb) from PYX-201, an investigational antibody-drug conjugate (ADC) developed by Pyxis Oncology. The assay was validated in rat and monkey plasma and used to support preclinical studies and an IND filing. The method demonstrated reliable quantification of PYX-201 across the validated ranges, providing a bioanalytical approach for measuring total antibody exposure during preclinical development. KCAS Bio contributed to the bioanalytical work, including assay development, validation, and sample analysis.
Read the article featured in the May 2023 edition of the Journal of Pharmaceutical and Biomedical Analysis
If you have any questions about these services or any others offered by KCAS Bio, please feel free to contact us using the form below.